Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

XTL Biopharmaceuticals Ltd ADR (XTLB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow XTL Biopharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.470 +0.070    +2.92%
27/04 - Closed. Currency in USD ( Disclaimer )
After Hours
2.400
-0.070
-2.834%
7:13:36 - Real-time Data
  • Volume: 5,242
  • Bid/Ask: 2.200 / 2.700
  • Day's Range: 2.405 - 2.490
Type:  Equity
Market:  United States
XTL Biopharma 2.470 +0.070 +2.92%

XTL Biopharmaceuticals Ltd ADR Company Profile

 
Get an in-depth profile of XTL Biopharmaceuticals Ltd ADR, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

5

Equity Type

ADR

XTL Biopharmaceuticals Ltd is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). hCDR1 is a peptide (short protein) that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Contact Information

Address 5 Badner Street
Ramat Gan, 5218102
Israel
Phone 972 3 611 6600
Fax 972 9 951 9708

Top Executives

Name Age Since Title
Daniel J. Wallace - - Member of Clinical Advisory Board
Osnat Hillel Fain 55 2015 Independent Non-Executive & External Director
Murray Urowitz - - Member of Clinical Advisory Board
Robert I. Fox - 2017 Member of Clinical Advisory Board
Lee S. Simon 70 - Member of Clinical Advisory Board
Simon Bowman - 2017 Member of Clinical Advisory Board
David Isenberg - 2015 Member of Clinical Advisory Board
Jonathan Schapiro 61 2014 Non-Executive Director
Shlomo Spokone Shalev 59 2014 CEO & Director
Doron Turgeman 53 2014 Non-Executive Chairman of the Board
Alexander Rabinovich 51 2017 Non-Executive Director
Dobroslav Melamed 46 2014 Independent Non-Executive Director
Iris Shapira Yalon 56 2020 Independent Non-Executive & External Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

XTLB Comments

Write your thoughts about XTL Biopharmaceuticals Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email